LAV MANAGEMENT COMPANY, LIMITED

Thesis

LAV MANAGEMENT COMPANY, LIMITED, including its related entities like Lilly Asia Ventures (LAV), operates as a venture capital and investment management firm with a strong focus on the biomedical and healthcare sectors. Their investment thesis centers on backing companies with breakthrough products in areas such as drug discovery, biopharmaceuticals, human therapeutics, medical devices, and diagnostics. LAV emphasizes "quality science and exceptional entrepreneurs," adopting a long-term investment horizon and avoiding speculative "quick flip" strategies. Geographically, the firm has a significant presence and focus on China and the United States, with offices in Hong Kong, Shanghai, and Palo Alto. The firm manages multiple funds, with AUM varying across entities, reaching up to $2 billion for LAV Investment Adviser Limited and $1.4 billion for LAV Global Management Company Limited. LAV Biosciences Fund III, L.P. has approximately $200.6 million in assets, and LAV Fund VII has a size of $700 million. The investment stages typically range from venture capital and growth stages, supporting companies from preclinical and clinical development through to market insights. While specific check sizes per deal are not disclosed, the fund sizes indicate substantial investment capacity. LAV originated in 2008 as a subsidiary of Eli Lilly and became independent in 2011. Some entities, like LAV Advanced Management Company Limited, appear to operate as single-family offices, prioritizing privacy.